Life Extension Magazine®

HIV and AIDS New Breakthroughs

New breakthroughs

Scientifically reviewed by: Dr. Gary Gonzalez, MD, in August 2023. Written by: Life Extension Editorial Staff.


HIV and AIDS: New Breakthroughs

STOP THE PRESS: HIV Treatment Protocol

As we were about to go to press with this issue of the magazine, preliminary findings were released indicating that various combinations of the anti-viral therapies (AZT, ddI, 3TC and Crixivan) along with a protease inhibitor showed remarkable success in 175 AIDS patients. In other studies using Crixivan (a chemical cousin to AZT), 13 of 22 patients had no detectable virus after five months; one patient on Crixivan had no detectable virus for two years. The cost of using these combination therapies was estimated at $11,400 a year.

Based on these preliminary reports, we make the following recommendations:

  1. If you are HIV positive and have a T-helper count of over 500, we suggest you consider as much of our AIDS TREATMENT PROTOCOL as you can afford.The three elements are:
    Nutritional Immune Support
    Hormonal Immune Support
    European Immune Support

    Have regular blood tests to monitor the efficacy of our AIDS TREATMENT PROTOCOL. Remember, based on the studies discussed in this article, delaying the use of toxic anti-viral drugs makes an individual's HIV virus more susceptible to anti-viral drug combinations.

  2. If you've had at least one opportunistic infection, and have T-helper cells below 500, you should consider these new aggressive anti-viral drug combinations ($11,400 a year). In order to protect your body against the known toxicity of these drugs, we suggest you follow our Nutritional Immune Support and Hormonal Immune Support protocols. Most of these nutrients and hormones are well documented to protect against anti-viral drug toxicity. We will keep you informed in future issues of LIFE EXTENSION Magazine about the long-term successes and toxicities of these new anti-viral drug combinations.

Exciting New Studies Bring Hope

Two recent studies have indicated that non-toxic substances may inhibit HIV The January issue of Arthritis and Rheumatism reported that a quinine based drug dramatically decreased AIDS-associated arthritis, inhibited HIV replication, and had a positive effect on a immunity. Although the study involved 2 patients, a previous study on 40 patients drew the same conclusions. The beneficial effects of the bark of the cinchona tree (from which quinine drugs are made) have been known for thousands of years. Atabrine and Plaquenil are 2 quinine-based drugs.

A study published in Blood shows that vitamin B, inhibits HIV in the test tube. And researchers in Florida have shown that DHEA inhibits FIV, the feline version of HIV, in the test tube.